Celladon to push heart failure gene therapy into Phase III on positive mid-stage data
This article was originally published in Scrip
Executive Summary
Celladon's Mydicar (SERCA2a gene therapy) improved outcomes and symptoms of advanced heart failure in its first Phase II trial. The privately held company presented the results from CUPID this week at the Annual Heart Failure Association of the European Society of Cardiology meeting in Berlin.